Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | HMGCR | P04035 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.31 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
| ▸ | FYN | P06241 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL85493 | 0.81 | TSHR (0.57) | TSHRALDH1A1HMGCRCHRM1TBXA2R | |
| SCHEMBL5464435 | 0.79 | TSHR (0.56) | TSHRALDH1A1HMGCRCHRM1TBXA2R | |
| Ammonia Solution, Strong SCHEMBL28635068 | 0.77 | TSHR (0.53) | TSHRALDH1A1HMGCRCHRM1TBXA2R | |
| Ammonia Solution, Strong SCHEMBL28635066 | 0.77 | TSHR (0.53) | TSHRALDH1A1HMGCRCHRM1TBXA2R | |
| SCHEMBL27667108 | 0.76 | TSHR (0.53) | TSHRALDH1A1HMGCRCHRM1TBXA2R | |
| SCHEMBL17373265 | 0.76 | TSHR (0.53) | TSHRALDH1A1HMGCRCHRM1TBXA2R | |
| SCHEMBL3112519 | 0.76 | TSHR (0.53) | TSHRALDH1A1HMGCRCHRM1TBXA2R | |
| SCHEMBL28302008 | 0.76 | TSHR (0.53) | TSHRALDH1A1HMGCRCHRM1TBXA2R | |
| SCHEMBL301639 | 0.74 | TSHR (0.50) | TSHRALDH1A1HMGCRCHRM1TBXA2R | |
| SCHEMBL14573217 | 0.74 | TSHR (0.50) | TSHRALDH1A1HMGCRCHRM1TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| US-20180208609-A1 | BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-07-26 | — | — | US | disclosed |
| EP-3019196-B1 | COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-06-06 | — | — | EP | disclosed |
| EP-2802326-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-04-18 | — | — | EP | disclosed |
| US-20180002350-A1 | BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-01-04 | — | — | US | disclosed |
| US-9770439-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-26 | — | — | US | disclosed |
| US-9770439-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-26 | — | — | US | disclosed |
| US-20130165390-A1 | BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| EP-2558577-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2013-02-20 | — | — | EP | disclosed |
| WO-2011127933-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2011-10-20 | — | — | WO | disclosed |
| CN-1934101-B | Dehydrophenylahistine and analogs thereof and synthesis of dehydrophenylahistine and analogs thereof | NEREUS PHARMACEUTICALS INC | 2011-10-12 | — | — | CN | disclosed |
| CN-102164917-A | Sulfonyl compounds that selectively modulate the CB2 receptor | BOEHRINGER INGELHEIM INT | 2011-08-24 | — | — | CN | disclosed |
| CN-101633655-A | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof | NEREUS PHARMACEUTICALS INC | 2010-01-27 | — | — | CN | disclosed |
| US-20090325903-A1 | BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| CN-100540548-C | Dehydrophenylahistine and analogs thereof and synthesis of dehydrophenylahistine and analogs thereof | NEREUS PHARMACEUTICALS INC (US) | 2009-09-16 | — | — | CN | disclosed |
| CN-1934101-A | Dehydrophenylahistine and analogs thereof and synthesis of dehydrophenylahistine and analogs thereof | NEREUS PHARMACEUTICALS INC (US) | 2007-03-21 | — | — | CN | disclosed |
| CN-1684955-A | Dehydrophenylahistine and analogs thereof and synthesis of dehydrophenylahistine and analogs thereof | NEREUS PHARMACEUTICALS INC (US) | 2005-10-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325903-A1 | BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | PSMB5, PSMB11, PSMB3 | TSHR 3330/4885ALDH1A1 3884/4885HMGCR 613/4885 |
| US-20180002350-A1 | BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | PSMB5, PSMB11, PSMB3 | TSHR 3330/4885ALDH1A1 3884/4885HMGCR 613/4885 |
| US-20180208609-A1 | BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | PSMB5, PSMB11, PSMB3 | TSHR 3330/4885ALDH1A1 3884/4885HMGCR 613/4885 |
| US-20130165390-A1 | BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | PSMB5, PSMB11, PSMB3 | TSHR 3330/4885ALDH1A1 3884/4885HMGCR 613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.